Impact of 18F-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy
dc.contributor.author | Lawal, Ismaheel Opeyemi | |
dc.contributor.author | Marcus, Charles | |
dc.contributor.author | Schuster, David M. | |
dc.contributor.author | Goyal, Subir | |
dc.contributor.author | Adediran, Omotayo A. | |
dc.contributor.author | Dhere, Vishal R. | |
dc.contributor.author | Joshi, Shreyas S. | |
dc.contributor.author | Abiodun-Ojo, Olayinka A. | |
dc.contributor.author | Master, Viraj A. | |
dc.contributor.author | Patel, Pretesh R. | |
dc.contributor.author | Fielder, Bridget | |
dc.contributor.author | Goodman, Mark | |
dc.contributor.author | Shelton, Joseph W. | |
dc.contributor.author | Kucuk, Omer | |
dc.contributor.author | Hershatter, Bruce | |
dc.contributor.author | Halkar, Raghuveer K. | |
dc.contributor.author | Jani, Ashesh B. | |
dc.date.accessioned | 2023-10-11T11:27:27Z | |
dc.date.issued | 2023-04 | |
dc.description.abstract | Please read abstract in the article. | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.embargo | 2023-12-14 | |
dc.description.sponsorship | The EMPIRE-1 trial received funding from the National Institutes of Health/National Cancer Institute (R01 CA16918), Blue Earth Diagnostics, Ltd., and the Winship Cancer Institute of Emory University. | en_US |
dc.description.uri | http://journals.lww.com/nuclearmed/pages/default.aspx | en_US |
dc.identifier.citation | Lawal, I.O., Marcus, C., Schuster, D.M. et al. 2023, 'Impact of F-18-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy', Clinical Nuclear Medicine, vol. 48, no. 4, pp. E153-E159, doi : 10.1097/RLU.0000000000004590. | en_US |
dc.identifier.issn | 0363-9762 (print) | |
dc.identifier.issn | 1536-0229 (online) | |
dc.identifier.other | 10.1097/RLU.0000000000004590 | |
dc.identifier.uri | http://hdl.handle.net/2263/92828 | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams and Wilkins | en_US |
dc.rights | © 2023 Wolters Kluwer Health / Lippincott Williams & Wilkins. This is a non-final version of an article published in final form in Clinical Nuclear Medicine, vol. 48, no. 4, pp. E153-E159, doi : 10.1097/RLU.0000000000004590. | en_US |
dc.subject | 18F-fluciclovine PET/CT imaging | en_US |
dc.subject | Positron emission tomography/computed tomography (PET/CT) | en_US |
dc.subject | Failure-free survival (FFS) | en_US |
dc.subject | Salvage radiotherapy (SRT) | en_US |
dc.subject | Prostate cancer | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | Biochemical recurrence (BCR) | en_US |
dc.title | Impact of 18F-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy | en_US |
dc.type | Postprint Article | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: